SAB Biotherapeutics (SABS)
NASDAQ:SABS
Want to see SABS full AI Analyst Report?
SABS Stock Chart & Stats
$3.85
$0.50(13.16%)
At close: 4:00 PM EST
$3.85
$0.50(13.16%)
Day’s Range― - ―
52-Week Range$1.65 - $6.60
Previous CloseN/A
Volume58.44K
Average Volume (3M)398.22K
Market Cap
$298.21M
Enterprise Value$20.64M
Total Cash (Recent Filing)$107.39M
Total Debt (Recent Filing)$6.17M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 06, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding76,464,096
10 Day Avg. Volume357,955
30 Day Avg. Volume398,221
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.65
Enterprise Value/Ebitda7.02
Forecast
1Y Price Target
$12.00Price Target Upside211.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Tc Bovine PlatformSAB's Tc bovine platform is a durable technological moat: it enables production of fully human, high‑titer polyclonal antibodies across multiple indications. Platform breadth supports repeatable programs, partner interest, and long‑term pipeline optionality beyond any single candidate.
Balance Sheet FlexibilityLow leverage and a materially larger equity base reduce near‑term solvency risk and give management runway to fund clinical programs. This structural financial flexibility mitigates liquidity shocks and supports strategic choices over the next several quarters without immediate debt pressure.
Positive Phase 1 SAB-142 DataRobust Phase 1 signals that SAB-142 preserves C‑peptide and shows mechanistic immunomodulation provide durable clinical validation. This strengthens the program's scientific rationale, boosts likelihood of advancing in Phase 2b, and enhances partner and payer interest for long‑term development.
Bears Say
Near-zero Revenue And Negative MarginsSAB lacks a recurring commercial revenue base and shows persistent negative gross profit and operating losses. Structurally, this means the company cannot self‑fund operations from product sales, increasing reliance on external financing and slowing progress toward sustainable profitability.
Weak Cash Generation / Cash BurnSustained negative operating and free cash flow create ongoing funding needs that pressure strategic flexibility. Persistent burn raises the probability of future dilution or constrained R&D/clinical investment, limiting the firm's ability to self‑finance pivotal trials or commercialization readiness.
Binding Manufacturing CommitmentThe exclusive, minimum‑spend manufacturing agreement ties commercialization to a single supplier and creates material post‑approval financial commitments. Structurally this reduces manufacturing flexibility, can raise fixed commercialization costs, and creates execution risk if demand or pricing dynamics shift.
SAB Biotherapeutics News
SABS FAQ
What was SAB Biotherapeutics’s price range in the past 12 months?
SAB Biotherapeutics lowest stock price was $1.65 and its highest was $6.60 in the past 12 months.
What is SAB Biotherapeutics’s market cap?
SAB Biotherapeutics’s market cap is $298.21M.
When is SAB Biotherapeutics’s upcoming earnings report date?
SAB Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 49 days.
How were SAB Biotherapeutics’s earnings last quarter?
SAB Biotherapeutics released its earnings results on May 12, 2026. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.212 by -$0.138.
Is SAB Biotherapeutics overvalued?
According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued.
Does SAB Biotherapeutics pay dividends?
SAB Biotherapeutics does not currently pay dividends.
What is SAB Biotherapeutics’s EPS estimate?
SAB Biotherapeutics’s EPS estimate is -0.27.
How many shares outstanding does SAB Biotherapeutics have?
SAB Biotherapeutics has 76,464,096 shares outstanding.
What happened to SAB Biotherapeutics’s price movement after its last earnings report?
SAB Biotherapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.212. Following the earnings report the stock price went down -2.688%.
Which hedge fund is a major shareholder of SAB Biotherapeutics?
Currently, no hedge funds are holding shares in SABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SAB Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (211.69% Upside)
$12.00 (211.69% Upside)
Hedge Fund Trend
Increased
By 4.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.05%
12-Months-Change
Fundamentals
Return on Equity
-0.29%
Trailing 12-Months
Asset Growth
551.81%
Trailing 12-Months
Company Description
SAB Biotherapeutics
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing immunotherapies built upon human antibodies. The company leverages sophisticated genetic engineering and antibody research to cultivate specialized transchromosomic bovine herds. These unique animals are engineered to generate fully human antibodies, which are then directed against a variety of specific ailments. This broad scope includes infectious diseases such as COVID-19 and influenza, various immune and autoimmune conditions like type 1 diabetes, and potential applications in organ transplantation and cancer treatment. Central to their strategy is the proprietary DiversitAb immunotherapy platform, which yields wholly human polyclonal antibodies, thereby circumventing the need for human donors. Key assets in their clinical pipeline feature SAB-185, a fully human polyclonal antibody therapeutic currently undergoing Phase III trials for COVID-19, and SAB-176, another fully human polyclonal antibody in development for the prevention or treatment of severe influenza. Additionally, their preclinical portfolio contains SAB-142, intended for autoimmune disorders such as type 1 diabetes and for managing organ transplant induction/rejection. Established in 2014, SAB Biotherapeutics is based in Sioux Falls, South Dakota.
SABS Earnings Call
Q1 2026
0:00 / 0:00
SABS Stock 12 Month Forecast
Average Price Target
$12.00
▲(211.69% Upside)
Technical Analysis
Ownership Overview
17.39% Insiders
3.41% Mutual Funds
68.17% Other Institutional Investors
7.52% Public Companies and
Individual Investors